Morphic Therapeutic to Participate in GI/Microbiome Panel Discussion at the 41st Annual Cowen Health Care ConferenceGlobeNewsWire • 02/16/21
Morphic Expands Research and Development Collaboration with Janssen Through Third Integrin ProgramGlobeNewsWire • 01/05/21
Morphic Therapeutic to Present at the Virtual 39th Annual J.P. Morgan Healthcare ConferenceGlobeNewsWire • 12/30/20
Morphic Therapeutic to Present at the Jefferies Virtual London Healthcare ConferenceGlobeNewsWire • 11/17/20
Morphic Announces Corporate Highlights and Third Quarter 2020 Financial ResultsGlobeNewsWire • 11/09/20
Morphic Announces Presentation of New Data Supporting Development of MORF-057 at UEG Week Virtual 2020GlobeNewsWire • 10/12/20
Morphic Therapeutic Announces First Healthy Volunteers Dosed in Phase 1 Clinical Trial of MORF-057GlobeNewsWire • 09/23/20
Morphic Therapeutic to Present at the Jefferies Next Generation IBD Therapeutics Virtual SummitGlobeNewsWire • 09/21/20
Morphic Announces that AbbVie Exercises License Option to αvβ6 Integrin Inhibitor Program, Including MORF-720, for Fibrotic DiseasesGlobeNewsWire • 08/25/20
Morphic Holding, Inc. (MORF) Reports Q2 Loss, Tops Revenue EstimatesZacks Investment Research • 08/10/20
Morphic Announces Corporate Highlights and Second Quarter 2020 Financial ResultsGlobeNewsWire • 08/10/20
Morphic Holding, Inc. (MORF) May Report Negative Earnings: Know the Trend Ahead of Q2 ReleaseZacks Investment Research • 08/03/20
Morphic Therapeutic Presents Positive Preclinical Data Supporting Development of MORF-057 in Inflammatory Bowel Disease at Digestive Disease Week 2020GlobeNewsWire • 06/29/20
Morphic to Present at the BMO 2020 Prescriptions for Success Healthcare Virtual ConferenceGlobeNewsWire • 06/18/20
Morphic Announces Appointment of Marc Schegerin, M.D., as Chief Financial Officer and Chief Operating OfficerGlobeNewsWire • 04/07/20
Morphic Presents Positive Preclinical Data Supporting MORF-057 as an Oral Inhibitor of the α4β7 Integrin and Potential Treatment for Inflammatory Bowel DiseaseGlobeNewsWire • 02/14/20